Methods: A systematic review identified population-based studies reporting on the prevalence of CD or UC after 1990 in Canada and the US. Data on prevalence was extracted and negative binomial models were created to predict the prevalence of CD and UC in Canada and the US from 2010 to 2030. Change in prevalence over time was reported as an annual percentage change (APC) with 95% confidence interval (CI). Extrapolated population data from Statistics Canada and the US Census Bureau were used to estimate the total number of individuals at risk for IBD in 2015 and 2025. The Consumer Price Indexes for each country were used to extrapolate direct medical costs for IBD in Canada and the US in 2015 and 2025, in their respective currencies.

Results: In 2015 the prevalence of IBD is 0.52% and 1,870,181 are estimated to be living with IBD in North America (Table 1). Over the next decade the prevalence of IBD in North America will increase by 2.39% per year (95% CI: 1.39%, 3.41%)(Table 1). Between 2015 and 2025 the prevalence of CD will rise significantly in Canada (APC= 3.75; 95% CI: 2.57, 4.93) and the US (APC= 3.30; 95% CI: 0.17, 6.53); however, the prevalence will remain stable for UC (Table 1). By 2025 approximately 0.9% of Canadians and 0.6% of Americans will have IBD. In 2025 the number of individuals with IBD in North America is estimated to be 2,571,653 with direct healthcare costing over $27 billion (Table 1).